Novartis Canada
Published on Novartis Canada (https://www.novartis.ca)

Home > Printer-friendly > Pharmaceuticals

Pharmaceuticals [1]

Over the past decade, Novartis Pharmaceuticals Canada has introduced 20 new medicines that have had an important impact on patients suffering from a wide variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation and osteoporosis.

Tab: 

A [2]


Aclasta* (zoledronic acid injection) 
Bone Metabolism Regulator

Consumer Information [3]

Product Monograph [4]

Important information for healthcare professionals (2010) [5]

Public Communication (2010) [6]

Important information for healthcare professionals (2005) [7]

Public Communication (2005) [8]

*Aclasta is a registered trademark


Afinitor* / Afinitor* DISPERZ** (everolimus tablets) 
mTOR Kinase Inhibitor

Product Monograph [9]

Patient Medication Information [10]

*Afinitor is a registered trademark **DISPERZ is a trademark


Aimovig* (erenumab) 
Anti-Calcitonin gene-related peptide receptor (anti-CGRPR)

Patient Medication Information [11]

Product Monograph [12]

*AIMOVIG is a trademark of Amgen Inc. used under license by Novartis Pharmaceuticals Canada Inc.


Alomide* (Lodoxamide)  
Anti-allergy Agent

Consumer Information [13]

Product Monograph [14]

*Alomide is a trademark of Novartis



Atectura* (Indacaterol (as acetate)/mometasone furoate inhalation powder hard capsules)
Bronchodilator and Inhaled Corticosteroid

Patient Medication Information [15]

Product Monograph [16]

*ATECTURA and BREEZHALER are registered trademarks

 


Atriance* (Nelarabine Injection) 
Antineoplastic Agent

Consumer Information [17]

Product Monograph [18]

*ATRIANCE is a registered trademark


Azarga* (brinzolamide and timolol)  
Topical Carbonic Anhydrase Inhibitor and Topical Beta-Adrenergic Blocking Agent

Consumer Information [19]

Product Monograph [20]

*Azarga is a Novartis product


Azopt* (Brinzolamide Ophthalmic Suspension) 
Topical Carbonic Anhydrase Inhibitor

Consumer Information [21]

Product Monograph [22]

*Azopt is a trademark of Novartis


 

 

B [23]


Beovu* (brolucizumab injection)
Ophthalmological / Antineovascularisation agent

Patient Medication Information [24]

Product Monograph [25]

Important Safety Information (2022) [26]

*BEOVU is a registered trademark
 


Betoptic S* (Betaxolol Hydrochloride Ophthalmic Suspension) 
Antiglaucoma Agent (Ophthalmic)

Consumer Information [27]

Product Monograph [28]

*a trademark of Novartis


 


 

C [29]


Ciloxan* (ciprofloxacin hydrochloride)
Antibacterial Agent

Product Monograph [30]

Patient Medication Information (Ointment) [31]

Patient Medication Information (solution) [32]

*Ciloxan is a trademark of Novartis
 


CiproDex* (Ciprofloxacin /Dexamethasone Otic Suspension)
Antibacterial - Corticosteroid (Otic)

Consumer Information [33]

Product Monograph [34]

*a trademark of Novartis
 


Cosentyx* (secukinumab)
Biological Response Modifier

Product Monograph [35]

Patient Medication Information [36]

*COSENTYX and SensoReady are registered trademarks
 


 

D [37]


Desferal* (deferoxamine mesylate for injection)
Iron and Aluminum Chelating Agent

Consumer Information [38]

Product Monograph [39]

*Desferal is a registered trademark
 


Diovan* (valsartan)
Angiotensin II AT1 Receptor Blocker

Consumer Information [40]

Product Monograph [41]

*Diovan is a registered trademark
 


Diovan*-HCT (valsartan and hydrochlorothiazide)
Angiotensin II AT1 Receptor Blocker and Diuretic

Consumer Information [42]

Product Monograph [43]

*Diovan is a registered trademark
 


DuoTrav PQ* (travoprost/timolol)
Prostaglandin F2a analogue and beta-adrenergic receptor blocker

Consumer Information [44]

Product Monograph [45]

*DuoTrav is a trademark of Novartis
 


Durezol* (difluprednate)
Topical Corticosteroid

Consumer Information [46]

Product Monograph [47]

*Durezol is a Novartis product
 


 

E [48]


 

Enerzair* Breezhaler* (Indacaterol (as acetate) / glycopyrronium (as bromide) / mometasone furoate inhalation powder)
Bronchodilator and Inhaled Corticosteroid

Patient Medication Information [49]

Product Monograph [50]

*ENERZAIR and BREEZHALER are registered trademarks

 


Entresto* (sacubitril/valsartan) 
Neutral endopeptidase inhibitor/Angiotensin II AT1 receptor blocker

Product Monograph [51]

Patient Medication Information [52]

*ENTRESTO is a trademark
 


Estalis* (norethindrone acetate and estradiol-17ß) 
Progestin-Estrogen

Consumer Information [53]

Product Monograph [54]

*Estalis is a registered trademark
 


Estradot* (estradiol-17ß) 
Estrogen

Consumer Information [55]

Product Monograph [56]

*Estradot is a registered trademark
 


Exelon* (rivastigmine hydrogen tartrate) 
Cholinesterase Inhibitor

Consumer Information [57]

Product Monograph [58]

Important information for healthcare professionals (2001) [59]

*Exelon is a registered trademark
 


Exelon* Patch (rivastigmine transdermal patch) 
Cholinesterase Inhibitor

Consumer Information [60]

Product Monograph [61]

Important information for healthcare professionals (2010) [62]

Public Communication (2010) [63]

*Exelon is a registered trademark
 


Exjade* (deferasirox) 
Iron Chelating Agent

Consumer Information [64]

Product Monograph [65]

Important information for healthcare professionals (2009) [66]

Public Communication (2009) [67]

Important information for healthcare professionals (2008) [68]

Public Communication (2008) [69]

Important information for healthcare professionals (2007) [70]

Public Communication (2007) [71]

*Exjade is a registered trademark
 


Extavia* (discontinued) (Interferon beta-1b) 
Immunomodulator

Consumer Information [72]

Product Monograph [73]

*Extavia is a registered trademark
 


 

F [74]


Femara* (letrozole) 
Non-steroidal aromatase inhibitor; Inhibitor of estrogen biosynthesis; Anti-tumour agent

Consumer Information [75]

Product Monograph [76]

Important information for healthcare professionals (2006) [77]

Important information for healthcare professionals (2005) [78]

Public Communication (2005) [79]

*Femara is a registered trademark
 


Flarex* (Fluorometholone Acetate)
Corticosteroid

Consumer Information [80]

Product Monograph [81]

*Flarex is a trademark of Novartis
 


Foradil* (formoterol fumarate) 
Bronchodilator

Patient Medication Information [82]

Product Monograph [83]

Important information for healthcare professionals (2005) [84]

*Foradil is a registered trademark
 


 

G [85]


Gilenya* (fingolimod (as fingolimod hydrochloride)) 
Sphingosine 1-phosphate receptor modulator

Patient Medication Information [86]

Product Monograph [87]

Important information for healthcare professionals (2012) [88]

Public Communication (2012) [89]

Health Product Risk Communication (2019) [90]

Important Safety Information - January 2021 [91]

www.gilenya.ca [92]

*Gilenya is a registered trademark
 


Gleevec* (imatinib mesylate) 
Protein Kinase Inhibitor

Consumer Information [93]

Product Monograph [94]

Important information for healthcare professionals (2009) [95]

Fact Sheet (2009) [96]

Important information for healthcare professionals (2006) [97]

Public Communication (2006) [98]

*Gleevec is a registered trademark
 


 

H [99]


Hycamtin* (Topotecan hydrochloride for Injection) 
Antineoplastic Agent

Consumer Information [100]

Product Monograph [101]

*HYCAMTIN is a registered trademark
 


 

I [102]


IZBA* (Travoprost ophthalmic solution) 
Elevated Intraocular Pressure Therapy

Patient Medication Information [103]

Product Monograph [104]

*IZBA is a trademark of Novartis


Ilaris* (canakinumab) 
Immunomodulator

Consumer Information [105]

Product Monograph [106]

*Ilaris is a registered trademark
 


Ilevro* (nepafenac)  
Nonsteroidal Anti-Inflammatory

Product Monograph [107]

Consumer Information [108]

*Ilevro is a Novartis product
 


Iopidine* (apraclonidine)  
Antiglaucoma Preparations and Miotics

Patient Medication Information [109]

Product Monograph [110]

*Iopidine is a trademark of Novartis
 


Isopto* Carpine (pilocarpine hydrochloride) 
Parasympathomimetic

Consumer Information [111]

Prescribing Information and Consumer Information [112]

*Isopto is a trademark of Novartis


 

J [113]


Jadenu* (Deferasirox) 
Iron Chelating Agent

Consumer Information [114]

Product Monograph [115]

Important information for healthcare professionals (2016) [116]

*Jadenu is a trademark
 


 

Jakavi* (ruxolitinib) 
Antineoplastic Agent

Consumer Information [117]

Product Monograph [118]

*Jakavi is a registered trademark
 


  

K [119]


 

Kesimpta* (ofatumumab)
Selective immunomodulator

Patient Medication Information [120]

Product Monograph [121]

*KESIMPTA is a trademark

 



Kisqali* (ribociclib)
Protein Kinase Inhibitor

Patient Medication Information [122]

Product Monograph [123]

*Kisqali is a trademark

 




Kymriah* (Tisagenlecleucel) 
Antineoplastic and immunomodulating agents

Patient Medication Information [124]

Product Monograph [125]

*KYMRIAH is a trademark

 

 

 

 

L [126]


Lamisil* (terbinafine hydrochloride) 
Antifungal Agent

Consumer Information [127]

Product Monograph [128]

Important information for healthcare professionals (2001) [129]

*Lamisil is a registered trademark


 

Leqvio* (Inclisiran)
Interfering Ribonucleic Acid Proprotein convertase subtilisin kexin type 9 inhibitor

Patient Medication Information [130]

Product Monograph [131]

*LEQVIO is a trademark

 


 

Lioresal* Intrathecal (baclofen injection) 
Antispastic Agent

Consumer Information [132]

Product Monograph [133]

*Lioresal is a registered trademark


Lopresor* / Lopresor SR* (discontinued) (metoprolol tartrate)
B - Adrenergic Receptor Blocking Agent

Consumer Information [134]

Product Monograph [135]

*Lopresor and Lopresor SR are registered trademarks


Lucentis* (ranibizumab injection) 
Antineovascularisation agent

Consumer Information [136]

Product Monograph [137]

*Lucentis is a registered trademark
 


 

Luxturna* (voretigene neparvovec)
Recombinant adeno-associated virus 2 vector-based gene therapy ATC S01XA27

Product Monograph [138]

Patient Medication Information [139]

*LUXTURNA is a registered trademark of Spark Therapeutics Inc., used under license by Novartis Pharmaceuticals Canada Inc.


 

M [140]


Maxidex* (dexamethasone) 
Corticosteroid

Consumer Information [141]

Prescribing Information [142]

*Maxidex is a trademark of Novartis

 

 


Maxitrol* (neomycin, polymyxin B sulfates and dexamethasone) 
Anti-inflammatory/Antibiotic

Consumer Information [143]

Prescribing Information [144]

*Maxitrol is a trademark of Novartis

 


Mayzent* (siponimod)
Sphingosine 1-phosphate receptor modulator

Product Monograph [145]

Patient Medication Information [146]

*MAYZENT is a trademark

 


Mekinist* (Trametinib Tablets) 
Protein Kinase Inhibitor

Patient Medication Information [147]

Product Monograph [148]

*MEKINIST is a registered trademark

 

 


Myfortic* (mycophenolic acid (as mycophenolate sodium)) 
Immunosuppressant

Consumer Information [149]

Product Monograph [150]

Important information for healthcare professionals (2009) [151]

Public Communication (2009) [152]

Important information for health care professionals (2016) [153]

*Myfortic is a registered trademark
 


 

N [154]


Neoral* (cyclosporine) 
Immunosuppressant

Consumer Information [155]

Product Monograph [156]

Neoral* Oral Solution-Recall Notice Lot H5131-January 2013 [157]

Recall of Lot H5131-Return Process-January 2013 [158]

*Neoral is a registered trademark
 


Nevanac* (nepafenac) 
Nonsteroidal Anti-Inflammatory

Consumer Information [159]

Product Monograph [160]

*a trademark of Novartis
 


 

O [161]


Onbrez* Breezhaler* (indacaterol maleate) 
Long-acting beta2-agonist

Product Monograph [162]

Patient Medication Information [163]

*Onbrez and Breezhaler are registered trademarks
 


 

P [164]


Pataday* (Olopatadine Hydrochloride) 
Anti-allergy Agent

Consumer Information [166]

Product Monograph [167]

*Pataday is a registered trademark of Novartis

 


Patanol* (Olopatadine Hydrochloride)  
Anti-allergy Agent

Consumer Information [168]

Product Monograph [169]

*Patanol is a Registered trademark of

 


Pazeo* (olopatadine) 
Anti-allergy Agent

Patient Medication Information [170]

Product Monograph [171]

*Pazeo is a trademark of Novartis
 


 

Piqray* (Alpelisib)
Antineoplastic Agent

Patient Medication Information [172]

Product Monograph [173]

*PIQRAY is a registered trademark

 

 

R [174]


Revolade* (Eltrombopag) 
Thrombopoietin Receptor Agonist

Consumer Information [175]

Product Monograph [176]

Important information for healthcare professionals (2021) [177]

Public Communication (2021) [178]

Important information for healthcare professionals (2016) [179]

*REVOLADE is a registered trademark
 

 


Rydapt* (midostaurine) 
Antineoplastic Agent

Consumer Information [180]

Product Monograph [181]

*Rydapt is a trademark
 


 

S [182]


Sandimmune* I.V. (cyclosporine) 
Immunosuppressant

Consumer Information [183]

Product Monograph [184]

*Sandimmune is a registered trademark

 

 


Sandostatin* / Sandostatin* LAR* (octreotide acetate injection) / (octreotide as acetate for injectable suspension) 
Synthetic Octapeptide Analogue of Somatostatin

Consumer Information [185]

Product Monograph [186]

*Sandostatin and LAR are registered trademarks

 

 


Seebri* Breezhaler* (glycopyrronium bromide) 
Long-acting muscarinic antagonist

Consumer Information [187]

Product Monograph [188]

*Seebri and Breezhaler are registered trademarks

 

 


Simbrinza* (brinzolamide / brimonidine tartrate)  
Topical Carbonic Anhydrase Inhibitor and Topical Alpha-2 Agonist Agent

Consumer Information [189]

Product Monograph [190]

*Simbrinza is a Novartis product

 

 


Simulect* (basiliximab) 
Immunosuppressant

Consumer Information [191]

Product Monograph [192]

*Simulect is a registered trademark

 


 

T [193]


 

Tabrecta* (capmatinib)
Protein Kinase Inhibitor

Patient Medication Information [194]

Product Monograph [195]

*TABRECTA is a registered trademark


 

Tafinlar* (Dabrafenib (as dabrafenib mesylate)) 
Protein Kinase Inhibitor

Patient Medication Information [196]

Product Monograph [197]

Important information for healthcare professionals (2015) [198]

*TAFINLAR is a registered trademark

 

 


Tasigna* (nilotinib) 
Protein-tyrosine Kinase Inhibitor

Consumer Information [199]

Product Monograph [200]

Important information for healthcare professionals (2013) [201]

Public Communication (2013) [202]

Important information for healthcare professionals (2011) [203]

Fact sheet (2011) [204]

Important information for healthcare professionals (2010) [205]

Fact Sheet (2010) [206]

Important information for healthcare professionals and patients (2016) [207]

*Tasigna is a registered trademark

 

 


Tegretol* (carbamazepine) 
Anticonvulsant, Antimanic, For Symptomatic Relief Of Trigeminal Neuralgia

Consumer Information [208]

Product Monograph [209]

Important information for healthcare professionals (2008) [210]

*Tegretol is a registered trademark

 

 


TobraDex* (Tobramycin and Dexamethasone)  
Antibacterial and Corticosteroid

Patient Medication Information [211]

Product Monograph including Patient Medication Information [212]

*Tobradex is a trademark of Novartis

 

 


Tobrex* (Tobramycin)  
Antibacterial (ophthalmic)

Product Monograph [213]

Patient Medication Information [214]

*Tobrex is a trademark of Novartis

 

 


Transderm-Nitro* (nitroglycerin) 
Antianginal Agent

Consumer Information [215]

Product Monograph [216]

*Transderm-Nitro is a registered trademark

 

 


Travatan* Z (Travoprost) 
Prostaglandin F2a analogue

Patient Medication Information [217]

Product Monograph including Patient Medication Information [218]

*Travatan is a trademark of Novartis

 

 


Triesence* (triamcinolone acetonide) 
Visualization Agent

Consumer Information [219]

Product Monograph [220]

*Triesence is a trademark of Novartis

 

 


Trileptal* (oxcarbazepine) 
Antiepileptic

Patient Medication Information [221]

Product Monograph [222]

Important information for healthcare professionals (2005) [223]

*Trileptal is a registered trademark 

 

 


Tykerb* (lapatinib tablets (as lapatinib ditosylate)) 
Antineoplastic Agent

Consumer Information [224]

Product Monograph [225]

Important information for healthcare professionals [226]

Public Communication (2013) [227]

*TYKERB is a registered trademark
 


 

U [228]


Ultibro* Breezhaler* (indacaterol maleate and glycopyrronium bromide) 
Long-acting beta2-agonist and Long-acting muscarinic antagonist

Consumer Information [229]

Product Monograph [230]

*Ultibro and Breezhaler are registered trademarks
 


 

V [231]



Vigamox* (Moxifloxacin Ophtalmic Solution) 
Antibacterial (ophtalmic)

Consumer Information [232]

Product Monograph [233]

*a trademark of Novartis

 

 


Voltaren Rapide* (diclofenac potassium) 
Nonsteroidal Anti-Inflammatory Drug (NSAID)

Consumer Information [234]

Product Monograph [235]

Important information for healthcare professionals (2014) [236]

Public Communication (2014) [237]

*Voltaren Rapide is a registered trademark

 

 


Voltaren* / Voltaren* SR (diclofenac sodium) 
Nonsteroidal Anti-Inflammatory Drug (NSAID)

Consumer Information [238]

Product Monograph [239]

Important information for healthcare professionals (2014) [240]

Public Communication (2014) [241]

*Voltaren is a registered trademark

 

 


Voltaren* Ophtha (Diclofenac Sodium) 
Anti-inflammatory Analgesic Agent

Consumer Information [242]

Product Monograph [243]

*Voltaren is a trademark of Novartis

 

 


Votrient* (Pazopanib (as pazopanib hydrochloride)) 
Antineoplastic Agent

Consumer Information [244]

Product Monograph [245]

Important information for healthcare professionals (2013) [246]

Public Communication (2013) [247]

*VOTRIENT is a registered trademark
 


 

X [248]


Xiidra* (Lifitegrast)
Lymphocyte function associated antigen-1 (LFA-1) antagonist

Patient Medication Information [249]

Product Monograph [250]

*XIIDRA is a registered trademark


Xolair* (omalizumab) 
IgE-Neutralizing Antibody (Anti-IgE)

Consumer Information [251]

Product Monograph [252]

*Xolair is a registered trademark
 


 

Z [253]


Zofran* / Zofran* ODT ((ondansetron hydrochloride dihydrate)) 
Antiemetic

Consumer Information [254]

Product Monograph [255]

Important information for healthcare professionals (2014) [256]

Important information for healthcare professionals (2012) [257]

Public Communication (2012) [258]

*ZOFRAN is a registered trademark

 


 Zolgensma* (onasemnogene abeparvovec)
Other drugs for disorders of the musculo-skeletal system

Product Monograph [259]

Patient Medication Information [260]

*ZOLGENSMA is a registered trademark

 


Zometa* (zoledronic acid for injection) 
Bone Metabolism Regulator

Consumer Information [261]

Product Monograph [262]

Important information for healthcare professionals (2005) [263]

Public Communication (2005) [264]

Important information for healthcare professionals (2004) [265]

*Zometa is a registered trademark

 

 


Zykadia* (Ceritinib) 
Protein Kinase Inhibitor

Consumer Information [266]

Product Monograph [267]

Important information for healthcare professionals (2015) [268]

*ZYKADIA is a registered trademark

 

 


 


Source URL: https://www.novartis.ca/en/our-products/pharmaceuticals

Links
[1] https://www.novartis.ca/en/our-products/pharmaceuticals
[2] https://www.novartis.ca/nos-produits/pharmaceutique#tab-1
[3] https://www.ask.novartispharma.ca/download.htm?res=aclasta_patient_e.pdf&resTitleId=97
[4] https://www.ask.novartispharma.ca/download.htm?res=aclasta_scrip_e.pdf&resTitleId=687
[5] https://www.ask.novartispharma.ca/download.htm?res=Aclasta_HPC_E_12Oct2010.pdf&resTitleId=285
[6] https://www.ask.novartispharma.ca/download.htm?res=Aclasta_PC_E_14Oct2010.pdf&resTitleId=286
[7] https://www.ask.novartispharma.ca/download.htm?res=Zometa_Aclasta DHCP_E_2005_Aug.pdf&resTitleId=230
[8] https://www.ask.novartispharma.ca/download.htm?res=Zometa_Aclasta_PC_E_2005_Aug.pdf&resTitleId=231
[9] https://www.ask.novartispharma.ca/download.htm?res=afinitor_scrip_e.pdf&resTitleId=705
[10] https://www.ask.novartispharma.ca/download.htm?res=afinitor_patient_e.pdf&resTitleId=1791
[11] https://www.ask.novartispharma.ca/download.htm?res=aimovig_patient_e.pdf&resTitleId=1522
[12] https://www.ask.novartispharma.ca/download.htm?res=aimovig_scrip_e.pdf&resTitleId=1480
[13] https://www.ask.novartispharma.ca/download.htm?res=alomide_patient_e.pdf&resTitleId=1309
[14] https://www.ask.novartispharma.ca/download.htm?res=alomide_scrip_e.pdf&resTitleId=1308
[15] https://www.ask.novartispharma.ca/download.htm?res=atectura_patient_e.pdf&resTitleId=1820
[16] https://www.ask.novartispharma.ca/download.htm?res=atectura_scrip_e.pdf&resTitleId=1821
[17] https://www.ask.novartispharma.ca/download.htm?res=atriance_patient_e.pdf&resTitleId=1078
[18] https://www.ask.novartispharma.ca/download.htm?res=atriance_scrip_e.pdf&resTitleId=1079
[19] https://www.ask.novartispharma.ca/download.htm?res=azarga_patient_e.pdf&resTitleId=1342
[20] https://www.ask.novartispharma.ca/download.htm?res=azarga_scrip_e.pdf&resTitleId=1310
[21] https://www.ask.novartispharma.ca/download.htm?res=azopt_patient_e.pdf&resTitleId=1350
[22] https://www.ask.novartispharma.ca/download.htm?res=azopt_scrip_e.pdf&resTitleId=1245
[23] https://www.novartis.ca/nos-produits/pharmaceutique#tab-2
[24] https://www.ask.novartispharma.ca/download.htm?res=beovu_patient_e.pdf&resTitleId=1649
[25] https://www.ask.novartispharma.ca/download.htm?res=beovu_scrip_e.pdf&resTitleId=1648
[26] https://www.ask.novartispharma.ca/download.htm?res=beovu_hprc_e.pdf&resTitleId=1843
[27] https://www.ask.novartispharma.ca/download.htm?res=betoptic_patient_e.pdf&resTitleId=1312
[28] https://www.ask.novartispharma.ca/download.htm?res=betoptic_scrip_e.pdf&resTitleId=1311
[29] https://www.novartis.ca/nos-produits/pharmaceutique#tab-3
[30] https://www.ask.novartispharma.ca/download.htm?res=ciloxan_scrip_e.pdf&resTitleId=1313
[31] https://www.novartis.ca/sites/www.novartis.ca/files/ciloxan_patient_o.pdf
[32] https://www.novartis.ca/sites/www.novartis.ca/files/ciloxan_patient_s.pdf
[33] https://www.ask.novartispharma.ca/download.htm?res=ciprodex_patient_e.pdf&resTitleId=1343
[34] https://www.ask.novartispharma.ca/download.htm?res=ciprodex_scrip_e.pdf&resTitleId=1344
[35] https://www.ask.novartispharma.ca/download.htm?res=cosentyx_scrip_e.pdf&resTitleId=990
[36] https://www.ask.novartispharma.ca/download.htm?res=cosentyx_patient_e.pdf&resTitleId=1767
[37] https://www.novartis.ca/nos-produits/pharmaceutique#tab-4
[38] https://www.ask.novartispharma.ca/download.htm?res=desferal_patient_e.pdf&resTitleId=246
[39] https://www.ask.novartispharma.ca/download.htm?res=desferal_scrip_e.pdf&resTitleId=736
[40] https://www.ask.novartispharma.ca/download.htm?res=diovan_patient_e.pdf&resTitleId=104
[41] https://www.ask.novartispharma.ca/download.htm?res=diovan_scrip_e.pdf&resTitleId=725
[42] https://www.novartis.ca/sites/www.novartis.ca/files/diovan%20hct_patient_e_0.pdf
[43] https://www.ask.novartispharma.ca/download.htm?res=diovan hct_scrip_e.pdf&resTitleId=726
[44] https://www.ask.novartispharma.ca/download.htm?res=duotravpq_patient_e.pdf&resTitleId=1318
[45] https://www.ask.novartispharma.ca/download.htm?res=duotravpq_scrip_e.pdf&resTitleId=1317
[46] https://www.ask.novartispharma.ca/download.htm?res=durezol_patient_e.pdf&resTitleId=1320
[47] https://www.ask.novartispharma.ca/download.htm?res=durezol_scrip_e.pdf&resTitleId=1319
[48] https://www.novartis.ca/nos-produits/pharmaceutique#tab-5
[49] https://www.novartis.ca/sites/www.novartis.ca/files/enerzair%20breezhaler_patient_e.pdf
[50] https://www.novartis.ca/sites/www.novartis.ca/files/enerzair%20breezhaler_scrip_e.pdf
[51] https://www.ask.novartispharma.ca/download.htm?res=entresto_scrip_e.pdf&resTitleId=1137
[52] https://www.ask.novartispharma.ca/download.htm?res=entresto_patient_e.pdf&resTitleId=1138
[53] https://www.ask.novartispharma.ca/download.htm?res=estalis_patient_e.pdf&resTitleId=112
[54] https://www.ask.novartispharma.ca/download.htm?res=estalis_scrip_e.pdf&resTitleId=737
[55] https://www.ask.novartispharma.ca/download.htm?res=estradot_patient_e.pdf&resTitleId=116
[56] https://www.ask.novartispharma.ca/download.htm?res=estradot_scrip_e.pdf&resTitleId=739
[57] https://www.ask.novartispharma.ca/download.htm?res=exelon_patient_e.pdf&resTitleId=118
[58] https://www.ask.novartispharma.ca/download.htm?res=exelon_scrip_e.pdf&resTitleId=740
[59] https://www.ask.novartispharma.ca/download.htm?res=Exelon DHCP_E_2001_Jan.pdf&resTitleId=253
[60] https://www.ask.novartispharma.ca/download.htm?res=exelon patch_patient_e.pdf&resTitleId=120
[61] https://www.ask.novartispharma.ca/download.htm?res=exelon patch_scrip_e.pdf&resTitleId=741
[62] https://www.ask.novartispharma.ca/download.htm?res=Exelon Patch_DHCP_E_Apr2010.pdf&resTitleId=254
[63] https://www.ask.novartispharma.ca/download.htm?res=Exelon Patch_PC_E_Apr2010.pdf&resTitleId=255
[64] https://www.ask.novartispharma.ca/download.htm?res=exjade_patient_e.pdf&resTitleId=122
[65] https://www.ask.novartispharma.ca/download.htm?res=exjade_scrip_e.pdf&resTitleId=689
[66] https://www.ask.novartispharma.ca/download.htm?res=Exjade DHCP_E_2009_Nov.pdf&resTitleId=256
[67] https://www.ask.novartispharma.ca/download.htm?res=Exjade PC_E_2009_Dec.pdf&resTitleId=257
[68] https://www.ask.novartispharma.ca/download.htm?res=Exjade DHCP_E_2008_Mar.pdf&resTitleId=258
[69] https://www.ask.novartispharma.ca/download.htm?res=Exjade PC_E_2008_Mar.pdf&resTitleId=259
[70] https://www.ask.novartispharma.ca/download.htm?res=Exjade DHCP_E_2007_Mar.pdf&resTitleId=260
[71] https://www.ask.novartispharma.ca/download.htm?res=Exjade PC_E_2007_Mar.pdf&resTitleId=261
[72] https://www.ask.novartispharma.ca/download.htm?res=extavia_patient_e.pdf&resTitleId=235
[73] https://www.ask.novartispharma.ca/download.htm?res=extavia_scrip_e.pdf&resTitleId=742
[74] https://www.novartis.ca/nos-produits/pharmaceutique#tab-6
[75] https://www.ask.novartispharma.ca/download.htm?res=femara_patient_e.pdf&resTitleId=126
[76] https://www.ask.novartispharma.ca/download.htm?res=femara_scrip_e.pdf&resTitleId=743
[77] https://www.ask.novartispharma.ca/download.htm?res=femara_hcp_e_09_2006.pdf&resTitleId=264
[78] https://www.ask.novartispharma.ca/download.htm?res=Femara_DHCP_E_2005_Nov.pdf&resTitleId=266
[79] https://www.ask.novartispharma.ca/download.htm?res=Femara PC_E_2005_Nov.pdf&resTitleId=267
[80] https://www.ask.novartispharma.ca/download.htm?res=flarex_patient_e.pdf&resTitleId=1322
[81] https://www.ask.novartispharma.ca/download.htm?res=flarex_scrip_e.pdf&resTitleId=1321
[82] https://www.ask.novartispharma.ca/download.htm?res=foradil_patient_e.pdf&resTitleId=1812
[83] https://www.ask.novartispharma.ca/download.htm?res=foradil_scrip_e.pdf&resTitleId=746
[84] https://www.ask.novartispharma.ca/download.htm?res=Foradil%20DHCP_E_2005_Sep.pdf&resTitleId=268
[85] https://www.novartis.ca/nos-produits/pharmaceutique#tab-7
[86] https://www.ask.novartispharma.ca/download.htm?res=gilenya_patient_e.pdf&resTitleId=1813
[87] https://www.ask.novartispharma.ca/download.htm?res=gilenya_scrip_e.pdf&resTitleId=747
[88] https://www.ask.novartispharma.ca/download.htm?res=Gilenya_HCP_E_21Aug2012.pdf&resTitleId=562
[89] https://www.ask.novartispharma.ca/download.htm?res=Gilenya_PC_E_23Aug2012.pdf&resTitleId=563
[90] https://www.ask.novartispharma.ca/download.htm?res=GILENYA%20HPRC%20Health%20Canada_E_19Dec2019.pdf&resTitleId=1624
[91] https://www.ask.novartispharma.ca/download.htm?res=gilenya_hprc_e.pdf&resTitleId=1729
[92] http://www.gilenya.ca/
[93] https://www.ask.novartispharma.ca/download.htm?res=gleevec_patient_e.pdf&resTitleId=174
[94] https://www.ask.novartispharma.ca/download.htm?res=gleevec_scrip_e.pdf&resTitleId=693
[95] https://www.ask.novartispharma.ca/download.htm?res=Gleevec_DHCP_E_2009_Dec.pdf&resTitleId=269
[96] https://www.ask.novartispharma.ca/download.htm?res=GLEEVEC_FactSheet_E_2009.pdf&resTitleId=270
[97] https://www.ask.novartispharma.ca/download.htm?res=Gleevec DHCP_E_2006_Sep21.pdf&resTitleId=271
[98] https://www.ask.novartispharma.ca/download.htm?res=Gleevec_PC_E_2006_Sep.pdf&resTitleId=272
[99] https://www.novartis.ca/nos-produits/pharmaceutique#tab-8
[100] https://www.ask.novartispharma.ca/download.htm?res=hycamtin_patient_e.pdf&resTitleId=1082
[101] https://www.ask.novartispharma.ca/download.htm?res=hycamtin_scrip_e.pdf&resTitleId=1083
[102] https://www.novartis.ca/nos-produits/pharmaceutique#tab-9
[103] https://ask.novartispharma.ca/download.htm?res=izba_patient_e.pdf&resTitleId=1279
[104] https://ask.novartispharma.ca/download.htm?res=izba_scrip_e.pdf&resTitleId=1278
[105] https://www.ask.novartispharma.ca/download.htm?res=ilaris_patient_e.pdf&resTitleId=234
[106] https://www.ask.novartispharma.ca/download.htm?res=ilaris_scrip_e.pdf&resTitleId=785
[107] https://www.ask.novartispharma.ca/download.htm?res=ilevro_scrip_e.pdf&resTitleId=1323
[108] https://www.ask.novartispharma.ca/download.htm?res=ilevro_patient_e.pdf&resTitleId=1324
[109] https://www.ask.novartispharma.ca/download.htm?res=iopidine_patient_e.pdf&resTitleId=1428
[110] https://www.ask.novartispharma.ca/download.htm?res=iopidine_scrip_e.pdf&resTitleId=1430
[111] https://www.ask.novartispharma.ca/download.htm?res=isopto%20carpine_patient_e.pdf&resTitleId=1353
[112] https://www.ask.novartispharma.ca/download.htm?res=isopto%20carpine_scrip_e.pdf&resTitleId=1325
[113] https://www.novartis.ca/nos-produits/pharmaceutique#tab-10
[114] https://www.ask.novartispharma.ca/download.htm?res=jadenu_patient_e.pdf&resTitleId=1184
[115] https://www.ask.novartispharma.ca/download.htm?res=jadenu_scrip_e.pdf&resTitleId=1183
[116] https://www.ask.novartispharma.ca/download.htm?res=jadenu_dhcp_2016_e.pdf&resTitleId=1185
[117] https://www.ask.novartispharma.ca/download.htm?res=jakavi_patient_e.pdf&resTitleId=524
[118] https://www.ask.novartispharma.ca/download.htm?res=jakavi_scrip_e.pdf&resTitleId=788
[119] https://www.novartis.ca/nos-produits/pharmaceutique#tab-11
[120] https://www.ask.novartispharma.ca/download.htm?res=kesimpta_patient_e.pdf&resTitleId=1735
[121] https://www.ask.novartispharma.ca/download.htm?res=kesimpta_scrip_e.pdf&resTitleId=1734
[122] https://www.ask.novartispharma.ca/download.htm?res=kisqali_patient_e.pdf&resTitleId=1438
[123] https://www.ask.novartispharma.ca/download.htm?res=kisqali_scrip_e.pdf&resTitleId=1439
[124] https://www.ask.novartispharma.ca/download.htm?res=kymriah_patient_e.pdf&resTitleId=1521
[125] https://www.ask.novartispharma.ca/download.htm?res=kymriah_scrip_e.pdf&resTitleId=1520
[126] https://www.novartis.ca/nos-produits/pharmaceutique#tab-12
[127] https://www.ask.novartispharma.ca/download.htm?res=lamisil_patient_e.pdf&resTitleId=137
[128] https://www.ask.novartispharma.ca/download.htm?res=lamisil_scrip_e.pdf&resTitleId=728
[129] https://www.ask.novartispharma.ca/download.htm?res=Lamisil DHCP_E_2001_May.pdf&resTitleId=273
[130] https://www.ask.novartispharma.ca/download.htm?res=leqvio_patient_e.pdf&resTitleId=1817
[131] https://www.ask.novartispharma.ca/download.htm?res=leqvio_scrip_e.pdf&resTitleId=1816
[132] https://www.ask.novartispharma.ca/download.htm?res=lioresalIT_patient_e.pdf&resTitleId=145
[133] https://www.ask.novartispharma.ca/download.htm?res=lioresalIT_scrip_e.pdf&resTitleId=803
[134] https://www.ask.novartispharma.ca/download.htm?res=lopresor_patient_e.pdf&resTitleId=148
[135] https://www.ask.novartispharma.ca/download.htm?res=lopresor_scrip_e.pdf&resTitleId=804
[136] https://www.ask.novartispharma.ca/download.htm?res=lucentis_patient_e.pdf&resTitleId=152
[137] https://www.ask.novartispharma.ca/download.htm?res=lucentis_scrip_e.pdf&resTitleId=795
[138] https://www.ask.novartispharma.ca/download.htm?res=luxturna_scrip_e.pdf&resTitleId=1710
[139] https://www.ask.novartispharma.ca/download.htm?res=luxturna_patient_e.pdf&resTitleId=1709
[140] https://www.novartis.ca/nos-produits/pharmaceutique#tab-13
[141] https://www.ask.novartispharma.ca/download.htm?res=maxidex_patient_e.pdf&resTitleId=1356
[142] https://www.ask.novartispharma.ca/download.htm?res=maxidex_scrip_e.pdf&resTitleId=1258
[143] https://www.ask.novartispharma.ca/download.htm?res=maxitrol_patient_e.pdf&resTitleId=1357
[144] https://www.ask.novartispharma.ca/download.htm?res=maxitrol_scrip_e.pdf&resTitleId=1260
[145] https://www.ask.novartispharma.ca/download.htm?res=mayzent_scrip_e.pdf&resTitleId=1645
[146] https://www.ask.novartispharma.ca/download.htm?res=mayzent_patient_e.pdf&resTitleId=1644
[147] https://www.ask.novartispharma.ca/download.htm?res=mekinist_patient_e.pdf&resTitleId=1788
[148] https://www.ask.novartispharma.ca/download.htm?res=mekinist_scrip_e.pdf&resTitleId=1087
[149] https://www.ask.novartispharma.ca/download.htm?res=myfortic_patient_e.pdf&resTitleId=158
[150] https://www.ask.novartispharma.ca/download.htm?res=myfortic_scrip_e.pdf&resTitleId=805
[151] https://www.ask.novartispharma.ca/download.htm?res=Myfortic DHCP_E_2009_Dec21.pdf&resTitleId=274
[152] https://www.ask.novartispharma.ca/download.htm?res=Myfortic PC_E_2009_Dec23.pdf&resTitleId=275
[153] https://www.ask.novartispharma.ca/download.htm?res=Myfortic DHCP_E_2016_Jan18.pdf&resTitleId=1162
[154] https://www.novartis.ca/nos-produits/pharmaceutique#tab-14
[155] https://www.ask.novartispharma.ca/download.htm?res=neoral_patient_e.pdf&resTitleId=160
[156] https://www.ask.novartispharma.ca/download.htm?res=neoral_scrip_e.pdf&resTitleId=691
[157] https://www.ask.novartispharma.ca/download.htm?res=NEORAL Recall Notice-E-08JA2013.pdf&resTitleId=625
[158] https://www.ask.novartispharma.ca/download.htm?res=Neoral Recall-Return Process-E-08JA2013.pdf&resTitleId=645
[159] https://www.ask.novartispharma.ca/download.htm?res=nevanac_patient_e.pdf&resTitleId=1328
[160] https://www.ask.novartispharma.ca/download.htm?res=nevanac_scrip_e.pdf&resTitleId=1327
[161] https://www.novartis.ca/nos-produits/pharmaceutique#tab-15
[162] https://www.ask.novartispharma.ca/download.htm?res=onbrez breezhaler_scrip_e.pdf&resTitleId=796
[163] https://www.ask.novartispharma.ca/download.htm?res=onbrez%20breezhaler_patient_e.pdf&resTitleId=1787
[164] https://www.novartis.ca/nos-produits/pharmaceutique#tab-16
[165] http://www.ask.novartispharma.ca/download.htm?res=phosphate novartis_patient_e.pdf&resTitleId=502
[166] https://www.ask.novartispharma.ca/download.htm?res=pataday_patient_e.pdf&resTitleId=1330
[167] https://www.ask.novartispharma.ca/download.htm?res=pataday_scrip_e.pdf&resTitleId=1331
[168] https://www.ask.novartispharma.ca/download.htm?res=patanol_patient_e.pdf&resTitleId=1333
[169] https://www.ask.novartispharma.ca/download.htm?res=patanol_scrip_e.pdf&resTitleId=1332
[170] https://www.ask.novartispharma.ca/download.htm?res=pazeo_patient_e.pdf&resTitleId=1435
[171] https://www.ask.novartispharma.ca/download.htm?res=pazeo_scrip_e.pdf&resTitleId=1434
[172] https://www.ask.novartispharma.ca/download.htm?res=piqray_patient_e.pdf&resTitleId=1653
[173] https://www.ask.novartispharma.ca/download.htm?res=piqray_scrip_e.pdf&resTitleId=1652
[174] https://www.novartis.ca/nos-produits/pharmaceutique#tab-17
[175] https://www.ask.novartispharma.ca/download.htm?res=revolade_patient_e.pdf&resTitleId=1091
[176] https://www.ask.novartispharma.ca/download.htm?res=revolade_scrip_e.pdf&resTitleId=1090
[177] https://www.ask.novartispharma.ca/download.htm?res=revolade_dhcp_e_2021.pdf&resTitleId=1841
[178] https://www.ask.novartispharma.ca/download.htm?res=revolade_pc_e_2021.pdf&resTitleId=1839
[179] https://www.ask.novartispharma.ca/download.htm?res=revolade_dhpc_e_aug2016.pdf&resTitleId=1241
[180] https://ask.novartispharma.ca/download.htm?res=rydapt_patient_e.pdf&resTitleId=1392
[181] https://ask.novartispharma.ca/download.htm?res=rydapt_scrip_e.pdf&resTitleId=1393
[182] https://www.novartis.ca/nos-produits/pharmaceutique#tab-18
[183] https://www.ask.novartispharma.ca/download.htm?res=sandimmune_patient_e.pdf&resTitleId=170
[184] https://www.ask.novartispharma.ca/download.htm?res=sandimmune_scrip_e.pdf&resTitleId=692
[185] https://www.ask.novartispharma.ca/download.htm?res=sandostatin_patient_e.pdf&resTitleId=1790
[186] https://www.ask.novartispharma.ca/download.htm?res=sandostatin_scrip_e.pdf&resTitleId=789
[187] https://www.ask.novartispharma.ca/download.htm?res=seebri breezhaler_patient_e.pdf&resTitleId=667
[188] https://www.ask.novartispharma.ca/download.htm?res=seebri breezhaler_scrip_e.pdf&resTitleId=797
[189] https://www.ask.novartispharma.ca/download.htm?res=simbrinza_patient_e.pdf&resTitleId=1335
[190] https://www.ask.novartispharma.ca/download.htm?res=simbrinza_scrip_e.pdf&resTitleId=1334
[191] https://www.ask.novartispharma.ca/download.htm?res=simulect_patient_e.pdf&resTitleId=362
[192] https://www.ask.novartispharma.ca/download.htm?res=simulect_scrip_e.pdf&resTitleId=809
[193] https://www.novartis.ca/nos-produits/pharmaceutique#tab-19
[194] https://www.ask.novartispharma.ca/download.htm?res=tabrecta_patient_e.pdf&resTitleId=1867
[195] https://www.ask.novartispharma.ca/download.htm?res=tabrecta_scrip_e.pdf&resTitleId=1866
[196] https://www.ask.novartispharma.ca/download.htm?res=tafinlar_patient_e.pdf&resTitleId=1789
[197] https://www.ask.novartispharma.ca/download.htm?res=tafinlar_scrip_e.pdf&resTitleId=1095
[198] https://www.ask.novartispharma.ca/download.htm?res=tafinlar_dhcp_mar2015_e.pdf&resTitleId=1096
[199] https://www.ask.novartispharma.ca/download.htm?res=tasigna_patient_e.pdf&resTitleId=186
[200] https://www.ask.novartispharma.ca/download.htm?res=tasigna_scrip_e.pdf&resTitleId=766
[201] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_DHCPL_E_April2013.pdf&resTitleId=707
[202] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_PC_E_April2013.pdf&resTitleId=706
[203] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_DHCPL_E_June 9 2011.pdf&resTitleId=338
[204] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_Fact Sheet_E_June 9 2011.pdf&resTitleId=339
[205] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_DHCPL_E_July2010.pdf&resTitleId=278
[206] https://www.ask.novartispharma.ca/download.htm?res=Tasigna_Fact Sheet_E_July2010.pdf&resTitleId=279
[207] https://www.novartis.ca/sites/www.novartis.ca/files/hprc_tkis_final_e.pdf
[208] https://www.ask.novartispharma.ca/download.htm?res=tegretol_patient_e.pdf&resTitleId=189
[209] https://www.ask.novartispharma.ca/download.htm?res=tegretol_scrip_e.pdf&resTitleId=813
[210] https://www.ask.novartispharma.ca/download.htm?res=Tegretol DHCP_E_2008_Mar.pdf&resTitleId=280
[211] https://www.ask.novartispharma.ca/download.htm?res=tobradex_patient_e.pdf&resTitleId=1361
[212] https://www.ask.novartispharma.ca/download.htm?res=tobradex_scrip_e.pdf&resTitleId=1363
[213] https://www.ask.novartispharma.ca/download.htm?res=tobrex_scrip_e.pdf&resTitleId=1394
[214] https://ask.novartispharma.ca/download.htm?res=tobrex_patient_e.pdf&resTitleId=1410
[215] https://www.ask.novartispharma.ca/download.htm?res=transderm-nitro_patient_e.pdf&resTitleId=195
[216] https://www.ask.novartispharma.ca/download.htm?res=transderm-nitro_scrip_e.pdf&resTitleId=814
[217] https://www.ask.novartispharma.ca/download.htm?res=travatan-z_patient_e.pdf&resTitleId=1347
[218] https://www.ask.novartispharma.ca/download.htm?res=travatan-z_scrip_e.pdf&resTitleId=1337
[219] https://www.ask.novartispharma.ca/download.htm?res=triesence_patient_e.pdf&resTitleId=1362
[220] https://www.ask.novartispharma.ca/download.htm?res=triesence_scrip_e.pdf&resTitleId=1338
[221] https://www.ask.novartispharma.ca/download.htm?res=trileptal_patient_e.pdf&resTitleId=1792
[222] https://www.ask.novartispharma.ca/download.htm?res=trileptal_scrip_e.pdf&resTitleId=787
[223] https://www.ask.novartispharma.ca/download.htm?res=Trileptal_DHLP_E_2005_Apr.pdf&resTitleId=281
[224] https://www.ask.novartispharma.ca/download.htm?res=tykerb_patient_e.pdf&resTitleId=1107
[225] https://www.ask.novartispharma.ca/download.htm?res=tykerb_scrip_e.pdf&resTitleId=1110
[226] https://www.ask.novartispharma.ca/download.htm?res=tykerb_dhcp_mar2013_e.pdf&resTitleId=1108
[227] https://www.ask.novartispharma.ca/download.htm?res=tykerb_pc_mar2013_e.pdf&resTitleId=1109
[228] https://www.novartis.ca/nos-produits/pharmaceutique#tab-20
[229] https://www.ask.novartispharma.ca/download.htm?res=ultibro%20breezhaler_patient_e.pdf&resTitleId=909
[230] https://www.ask.novartispharma.ca/download.htm?res=ultibro%20breezhaler_scrip_e.pdf&resTitleId=910
[231] https://www.novartis.ca/nos-produits/pharmaceutique#tab-21
[232] https://www.ask.novartispharma.ca/download.htm?res=vigamox_patient_e.pdf&resTitleId=1340
[233] https://www.ask.novartispharma.ca/download.htm?res=vigamox_scrip_e.pdf&resTitleId=1339
[234] https://www.ask.novartispharma.ca/download.htm?res=voltaren%20rapide_patient_e.pdf&resTitleId=213
[235] https://www.ask.novartispharma.ca/download.htm?res=voltaren rapide_scrip_e.pdf&resTitleId=817
[236] https://www.ask.novartispharma.ca/download.htm?res=Voltaren%20Voltaren%20SR%20Voltaren%20Rapide_HPC_E_06Oct2014.pdf&resTitleId=968
[237] https://www.ask.novartispharma.ca/download.htm?res=Voltaren%20Voltaren%20SR%20Voltaren%20Rapide_PC_E_06Oct2014.pdf&resTitleId=970
[238] https://www.ask.novartispharma.ca/download.htm?res=voltaren_patient_e.pdf&resTitleId=215
[239] https://www.ask.novartispharma.ca/download.htm?res=voltaren_scrip_e.pdf&resTitleId=818
[240] https://www.ask.novartispharma.ca/download.htm?res=Voltaren%20Voltaren%20SR%20Voltaren%20Rapide_HPC_E_06Oct2014.pdf&resTitleId=967
[241] https://www.ask.novartispharma.ca/download.htm?res=Voltaren%20Voltaren%20SR%20Voltaren%20Rapide_PC_E_06Oct2014.pdf&resTitleId=969
[242] https://www.ask.novartispharma.ca/download.htm?res=voltaren%20ophtha_patient_e.pdf&resTitleId=1370
[243] https://www.ask.novartispharma.ca/download.htm?res=voltaren%20ophtha_scrip_e.pdf&resTitleId=1371
[244] https://www.ask.novartispharma.ca/download.htm?res=votrient_patient_e.pdf&resTitleId=1100
[245] https://www.ask.novartispharma.ca/download.htm?res=votrient_scrip_e.pdf&resTitleId=1099
[246] https://www.ask.novartispharma.ca/download.htm?res=votrient_dhcp_aug2013_e.pdf&resTitleId=1103
[247] https://www.ask.novartispharma.ca/download.htm?res=votrient_pc_2013_e.pdf&resTitleId=1102
[248] https://www.novartis.ca/nos-produits/pharmaceutique#tab-22
[249] https://www.ask.novartispharma.ca/download.htm?res=xiidra_patient_e.pdf&resTitleId=1622
[250] https://www.ask.novartispharma.ca/download.htm?res=xiidra_scrip_e.pdf&resTitleId=1623
[251] https://www.ask.novartispharma.ca/download.htm?res=xolair_patient_e.pdf&resTitleId=217
[252] https://www.ask.novartispharma.ca/download.htm?res=xolair_scrip_e.pdf&resTitleId=800
[253] https://www.novartis.ca/nos-produits/pharmaceutique#tab-23
[254] https://www.ask.novartispharma.ca/download.htm?res=zofran_patient_e.pdf&resTitleId=1113
[255] https://www.ask.novartispharma.ca/download.htm?res=zofran_scrip_e.pdf&resTitleId=1114
[256] https://www.ask.novartispharma.ca/download.htm?res=zofran_dhcp_juin2014_f.pdf&resTitleId=1116
[257] https://www.ask.novartispharma.ca/download.htm?res=zofran_dhcp_oct2012_e.pdf&resTitleId=1115
[258] https://www.ask.novartispharma.ca/download.htm?res=zofran_pc_oct2012_e.pdf&resTitleId=1118
[259] https://prod.novartis.ca/sites/www.novartis.ca/files/zolgensma_scrip_e.pdf
[260] https://www.ask.novartispharma.ca/download.htm?res=zolgensma_patient_e.pdf&resTitleId=1748
[261] https://www.ask.novartispharma.ca/download.htm?res=zometa_patient_e.pdf&resTitleId=222
[262] https://www.ask.novartispharma.ca/download.htm?res=zometa_scrip_e.pdf&resTitleId=749
[263] http://www.ask.novartispharma.ca/download.htm?res=Zometa_Aclasta%20DHCP_E_2005_Aug.pdf&resTitleId=282
[264] https://www.ask.novartispharma.ca/download.htm?res=Zometa_Aclasta_PC_E_2005_Aug.pdf&resTitleId=283
[265] https://www.ask.novartispharma.ca/download.htm?res=Aredia_Zometa_DHCP_E_2004_Nov.pdf&resTitleId=284
[266] https://www.ask.novartispharma.ca/download.htm?res=zykadia_patient_e.pdf&resTitleId=1129
[267] https://www.ask.novartispharma.ca/download.htm?res=zykadia_scrip_e.pdf&resTitleId=1130
[268] https://www.ask.novartispharma.ca/download.htm?res=Zykadia_HCP_E_23Mar2015.pdf&resTitleId=1131